Results 181 to 190 of about 835,238 (391)

Report No. 19: Geographic Mobility in the European Union: Optimising its Economic and Social Benefits [PDF]

open access: yes
Joint expertise with NIRAS Consultants and AMS for the European Commission, Bonn 2008 (159 pages)
Bonin, Holger   +8 more
core  

Lactation Consultants’ Perceived Barriers to Providing Professional Breastfeeding Support

open access: yesJournal of Human Lactation, 2018
E. Anstey   +6 more
semanticscholar   +1 more source

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin   +10 more
wiley   +1 more source

Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement

open access: yesInfectious Diseases and Therapy
Introduction Weekly intravenous (IV) oritavancin and daily daptomycin were compared in an outpatient setting following extensive surgical debridement for treating patients with osteomyelitis.
Nicholas W. Van Hise   +5 more
doaj   +1 more source

Generating meaningful and easy-to-interpret sustainability data to support decision making: a method and a case study

open access: yesRevista Águas Subterrâneas, 2013
Recently many corporations, organizations, and governmental agencies are putting a greater emphasis on evaluating sustainability of projects and products to help guide implementation and production.
Matt Vanderkooy   +3 more
doaj  

CSF Mitochondrial DNA: Biomarker of Body Composition and Energy Metabolism in Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cerebrospinal fluid (CSF) cell‐free mitochondrial DNA (cf‐mtDNA) is a potential biomarker for Parkinson's disease (PD), but its clinical relevance remains unclear. We investigated associations between CSF cf‐mtDNA levels, body composition, nutritional status, and metabolic biomarkers in PD. Methods CSF cf‐mtDNA levels, defined as the
Yasuaki Mizutani   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy